Here are the 10-Q quarterly reports from Longevity Health Holdings WT (XAGEW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow XAGEW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XAGEW filings page.
Longevity Health Holdings, Inc. reported continued operating losses and severe liquidity pressure for the period ended June 30, 2026. Net sales were $787,755 for the first six months of 2026, down from $1,013,965 a year earlier, and the company recorded a net loss of $3,315,003. Gross profit was $472,561, while operating expenses fell meaningfully to $2,525,203 as management reduced selling, R&D, and G&A costs.
Cash and cash equivalents were only $35,471 with a working capital deficit of $8,881,397, negative operating cash flow of $709,172, and total liabilities of $9,754,695 versus total assets of $1,055,248. The company disclosed that these conditions raise substantial doubt about its ability to continue as a going concern and stated it will need additional debt or equity financing or cash-flow-generating acquisitions.
During 2026, Longevity completed a private placement of 689,656 shares for net proceeds of $190,001 and entered into a Shopify revolving facility, with $45,202 outstanding at quarter-end. After period-end, it settled litigation with Puritan Partners LLC by issuing $2,350,000 in new Senior Secured Convertible Notes bearing 10% interest and convertible at $0.50 per share, further leveraging the balance sheet.
Longevity Health Holdings (XAGE) filed its Q3 2025 10‑Q, reporting higher sales but ongoing losses and liquidity pressure. Net sales were $425,864, up sharply from $20,519 a year ago; nine‑month net sales reached $1,439,829. The company posted a Q3 net loss of $1,429,755 and a nine‑month loss of $4,822,060.
Cash rose to $1,109,228 from $157,139 at year‑end, aided by $4,139,212 of financing inflows, including a January private placement and a May at‑the‑market program, plus $1,000,000 of warrant exercises. Operating cash use was $3,022,899 for the nine months. Management disclosed substantial doubt about the ability to continue as a going concern, citing a working capital deficit of $3,997,047.
The company completed the Elevai asset acquisition in January, recording $660,805 of stock consideration and potential earnouts, and effected a 1‑for‑30 reverse stock split in May. As of November 12, 2025, common shares outstanding were 1,781,738. A merger agreement with THPlasma includes equity consideration mechanics and closing conditions, with no timing commitments stated here.